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Abstract:  A  simple  HPLC  method  was  developed  and  validated  for  quantitation  of 
carvedilol in dissolution medium and tablet dosage form. Chromatographic separation was 
achieved on a Alltima
® C18 (250 mm4.6 mm) column using a mobile phase containing 
0.01  M  Na2HPO4  in  water  and  acetonitrile  (30:70  v/v)  adjusted  to  pH  3.0  by  ortho-
phosphoric acid at a flow rate of 1.0 ml/min and employing fluorescence detection with 
300-  nm  excitation  and  343-nm  emission  wavelengths.  The  method  was  validated  for 
specificity, linearity, accuracy, precision and stability. Dissolution test parameters were also 
investigated.  Moreover,  the  proposed  analytical  method  was  applied  to  monitor  the 
formulation content uniformity and labelled amount of commercially available carvedilol 
drugs. 
Keywords:  carvedilol, HPLC, validation, dissolution test, quality control 
 
Introduction 
Carvedilol,  or  ()-1-9H-(carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol 
(Figure 1), is an antihypertensive agent with - and 1-adrenergic receptor blocking activities [1-3]. 
Carvedilol has much greater antioxidant activity than other commonly-used -blockers [4-5]. It has 
been prescribed as an antihypertensive agent and an angina agent [6-7] and for treatment of congestive 
heart failure [8].  
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Figure 1.  Chemical structure of carvedilol 
 
High-performance  liquid  chromatography  (HPLC)  with  fluorescence  detector  [9-14],  mass 
spectrometer [15-16] or electrochemical detection [17] has been used for the analysis of carvedilol and 
its enantiomers in biological samples. Determination of cavedilol by capillary electrophoresis has also 
been  reported  [14,18].  There  have  been  few  published  articles  on  the  evaluation  of  carvedilol  in 
pharmaceutical  formulations.  That  using  HPLC  with  UV  detector  [19-21]  and  differential  pulse 
voltammetric determination [22] have been presented. 
The dissolution test and quantitative assay are very important features of the quality control of 
drugs  in  the  pharmaceutical  industry.  The  dissolution  test  is  currently  used  as  an  in  vitro 
bioequivalence test and generally for obtaining dissolution profile and profile comparison to establish 
the similarity of pharmaceutical dosage  forms [23-24]. To the best of our knowledge, there  is  no 
official assay guideline for carvedilol in dosage forms and dissolution samples in any pharmacopoeia, 
nor any dissolution test for this pharmaceutical in dosage forms reported in the literature. Thus, in this 
paper  an  attempt  is  made  to  develop  and  validate  a  simple,  efficient  and  reliable  method  for  the 
determination  of  carvedilol  intended  for  pharmaceutical  applications  by  HPLC  using  fluorescence 
detection.  Carvedilol  assay  in  tablet  formulation  and  dissolution  samples  is  described  and  the 
optimisation of a dissolution protocol for carvedilol-containing tablets is presented. Evaluation of the 
dissolution profiles of two marketed carvedilol products by the optimised method is also reported. 
 
Materials and Methods 
Chemicals and reagents 
Standard carvedilol (99.91%) was obtained from Salutas Pharma GmbH (Barleben, Germany) 
and  was  used  as  certified  reference  compound  for  quantitative  analysis. Other  chemicals  were  of 
analytical reagent grade purchased from various sources. All solvents were of HPLC grade obtained 
from VWR Prolabo (Leuven, Belgium). All experiments were performed with purified water obtained 
from TKA ROS 300 (Niederelbert, Germany). 
 
Chromatographic conditions 
The HPLC system used for the assay consisted of a dual plunger pump (LC-10ATVP, Shimadzu, 
Kyoto, Japan), a  fluorescence detector (RF-10AXL, Shimadzu), a system controller (SCL-10AVP, 
Shimadzu) and a Rheodyne (7725) sample injector (Rohnert Park, CA) fitted with a 20-l sample loop. 
The separation was performed at ambient temperature on an Alltima
® C18 (250 mm4.6 mm i.d., 5 
m, 250  Å) column purchased  from  Alltech (Deerfield, IL). The column was  fitted with a guard 
column packed with C18 (4.0 mm3.0 mm i.d.; Phenomenex Torrance, CA). The mobile phase was a   
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mixture  of  0.01  M  Na2HPO4  in  water  and  acetonitrile  (30:70  v/v)  adjusted  to  pH  3.0  by  ortho-
phosphoric acid and had a flow rate of 1.0 ml/min. The mobile phase was degassed by ultrasonication 
prior to use and was allowed to recirculate during the analysis. The peak areas were determined using a 
fluorescence detector with excitation wavelength and emission wavelength set at 300 nm and 343 nm 
respectively [25]. 
 
Preparation of standard solutions 
A  stock  solution  of  carvedilol  (1  mg/ml)  was  prepared  with  the  mobile  phase  as  solvent. 
Calibration standard solutions were prepared by diluting the stock solution to 1, 5, 10, 20, 30 and 40 
g/ml with the dissolution medium. 
 
Analytical method validation 
Specificity: Specificity was assessed by examining peak interferences from dissolution medium. 
This was done by inspecting chromatograms of blank and spiked medium samples. 
Linearity: Six-point standard calibration curves were prepared over a concentration range of 1-
40  g/ml  for  carvedilol.  The  data  of  peak  area  versus  drug  concentration  were  constructed  by 
unweighted least-square linear regression analysis. 
Accuracy and precision: Accuracy and precision were determined from six replicates of each 
carvedilol concentration (1, 5, 10, 20, 30 and 40 g/ml) within the range of the calibration curve. 
Accuracy  and  precision  were  expressed  as  %  accuracy  and  %  coefficient  of  variation  (CV) 
respectively. 
Stability: The dissolution medium containing standard carvedilol was kept at 370.5C for 2 hr 
under  light shaking and then  left at room temperature for 24 hr. The response of the 24-hr aged 
solutions was evaluated against a freshly-prepared standard solution. 
 
Dissolution 
Dissolution of carvedilol tablets was optimised using Dilatrend
 (carvedilol tablets: 6.25, 12.5 
and 25 mg, manufactured by Roche S.p.A., Segrate, Italy). In each experiment, twelve tablets were 
randomly selected. Dissolution testing was performed in accordance with the USP <711> [26] using 
apparatus II (VK 10-1500, Vankel Industries Inc., Cary, NC). The dissolution apparatus was used with 
paddles at 50 rpm and a bath temperature of 370.5C. The dissolution media were evaluated using 0.1 
N HCl solution (pH 1.2), acetate buffer (pH 4.5) and phosphate buffer (pH 6.8) [26]. Dissolution was 
carried out according to the drug release guidelines [27]; 900 ml of the freshly prepared medium was 
used in a rotating vessel. At each sampling time point, the dissolution sample (5 ml)  was collected 
from  each  vessel  and  filtered  through  a  0.45-m  porosity  nitrocellulose  membrane  (Millipore, 
Bedford, MA). Fresh medium (5 ml) weas replaced in each vessel after sampling. A 20-l aliquot of 
each  sample  was  injected  into  the  HPLC  system  for  analysis.  The  quantity  of  carvedilol  in  the 
dissolution medium was calculated from a calibration curve. The results were estimated as % labelled 
amount of the dissolved active ingredient. 
 
  
Maejo Int. J. Sci. Technol.  2010, 4(01), 8-19 
 
11 
Application to drug quality controls: dissolution profile comparison 
Dilatrend
 (6.25, 12.5 and 25 mg) as reference product and the same does of Brand A (generic 
carvedilol tablets) as test product were studied. The procedure for dissolution as previously described 
above was followed. According to the US FDA guideline [28] for dissolution profile comparisons, the 
difference factor (f1) and similarity factor (f2) were calculated as follows: 
f1  = {(
n
t = 1 | Rt - Tt |) / (
n
t = 1 Rt)}  100 
f2  = 50  log {(1 + (1/n) 
n
t = 1 (Rt - Tt)
2) 
-0.5  100} 
in which Rt and Tt are the percentages of Dilatrend
 and Brand A respectively that were dissolved at 
each time point,  and n is the number of sampling time points. 
 
Assay in tablet formulation 
Standard preparation:  An accurately weighed  quantity of carvedilol working standard was 
dissolved in the mobile phase to afford a solution having a concentration of 0.025 mg/ml. 
Assay preparation: Twenty tablets of the test or reference product were weighed and then 
finely  powdered.  An  accurately  weighed  portion  of  the  powder,  equivalent  to  about  12.5  mg  of 
carvedilol, was transferred to a 50-ml volumetric flask and 20 ml of mobile phase was added. The 
volumetric flask was shaken mechanically for 5 min, sonicated for 10 min and diluted to volume. One 
ml of this solution was transferred to a 10-ml  volumetric  flask and diluted with  mobile phase to 
volume. A portion of this solution was filtered through a 0.45-m-porosity nylon filter membrane 
(Millipore). 
Procedure: A 20-l aliquot of standard or sample preparation (test and reference products) was 
injected into the HPLC system described above. The quantity (in mg) of carvedilol in the portion of 
tablets was obtained by the formula: 500 C (rU / rS), in which 500 is the dilution factor, C is the 
concentration (in mg/ml) of carvedilol in the standard preparation, and rU and rS are the carvedilol peak 
areas obtained from the assay and standard preparations respectively. The results were then estimated 
as % labelled amount. 
For the determination of dosage-unit uniformity by assay of individual units [26], 10 units each 
of the test and reference products were selected. Each tablet was finely powdered, transferred to a 50-
ml  volumetric  flask and diluted to volume.  A portion of this  solution was transferred to a 10-ml 
volumetric flask and diluted with mobile phase to volume, to afford a final concentration of 0.025 
g/ml. A portion of this solution was filtered through a 0.45-m-porosity nylon filter membrane and 
the filtrate (20l) was analysed by HPLC in the same manner as above. The content of carvedilol in 
each tablet was calculated by comparison with the standard solution at 0.025 g/ml.   
 
Results and Discussion 
Specificity and optimisation of chromatographic conditions 
The method demonstrates excellent chromatographic specificity with no interference from tablet 
excipients,  mobile phase or dissolution  medium  at the retention time of carvedilol. Representative 
chromatograms  of  carvedilol  in  the  three  dissolution  media  are  shown  in  Figure  2.  At  equal 
concentration,  a  smaller  peak  area  of  carvedilol  is  observed  in  the  phosphate  buffer  pH  6.8  as 
compared with those in the HCl solution pH 1.2 and the acetate buffer pH 4.5. Apparently, the pH of  
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the  medium  has  certain  effect  on  the  fluorescence  intensity  of  carvedilol.   The  retention  time  of 
carvedilol is 2.8 min and each analysis can be done within 4 min under specified conditions. 
 
 
(A) 
 
(B) 
 
(C) 
Figure 2.  Representative HPLC chromatograms of carvedilol (equal concentration) in: (A) 0.1 N HCl 
solution pH 1.2;  (B) acetate buffer pH 4.5;  (C) phosphate buffer pH 6.8  
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Method validation 
According to Category III of the compendial assay procedures [26], a minimal assessment is 
required in terms of linearity, accuracy, precision and stability in three different media. The calibration 
curves for carvedilol in all dissolution media show good linearity with regression coefficient greater 
than 0.99 in the concentration range of 1-40 g/ml. This means that there is a good correlation between 
peak area and drug concentration. The equation of linear regression and regression coefficient of the  
calibration curve for each medium is presented in Table 1. The results of the accuracy and precision 
determinations are shown in Table 2. The accuracy is between 95-105% and the intra-day precision 
expressed as % CV is less than 6.67% for the three dissolution media. The solutions remained stable in 
all dissolution media tested for the time period specified and no degradation products were observed in 
any chromatogram. 
 
Table 1.   Slope, intercept and regression coefficient of calibration curves obtained from three different 
dissolution media (n=6) 
 
Medium  Slope  Intercept  Regression coefficient 
0.1 N HCl solution 
pH 1.2 
124367.00  -25017.39  0.9994 
Acetate buffer 
pH 4.5 
117218.42  4996.24  0.9989 
Phosphate buffer 
pH 6.8 
122211.38  -22638.78  0.9981 
 
 
In vitro dissolution study 
A dissolution test is normally employed for lot-to-lot quality control of pharmaceuticals in solid 
dosage form. Since carvedilol is not officially available in the pharmacopoeia, we have developed the 
dissolution testing condition for this drug. Drug release was carried out in accordance with the US 
pharmacopoeia general methods (Apparatus II) [26]. The temperature was kept constant at 370.5C 
and the volume in each vessel kept at 900 ml. The dissolution parameters such as pH of medium, 
stirring speed and sampling time interval were optimised in terms of dissolution rate and precision. 
The  most suitable dissolution method is shown in Table 3. In all three dosage strengths, Dilatrend
 
exhibits delayed dissolution in phosphate buffer pH 6.8 (Figure 3C) compared with dissolution in HCl 
solution pH 1.2 (Figure 3A) and that in acetate buffer pH 4.5 (Figure 3B). From the dissolution profile 
(Figure 3), 12.5 mg of Dilatrend
 in HCl solution pH 1.2 and acetate buffer pH 4.5 show fastest 
dissolution. The different dissolution rates might stem from the difference in solubility in different pH 
media. For routine quality control test using a single-point specification [26], the acceptance criteria of 
tolerance should be at least 80% (Q) dissolution within 30 min in acetate buffer pH 4.5. 
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Table 2.   Accuracy and precision of the method for determining the concentration of carvedilol in 
three dissolution media (n=6) 
 
Medium  Actual 
concentration 
Detected 
concentration 
Accuracy  Precision 
  (g/ml)  (Mean  SD; g/ml)  (%Accuracy)  (%CV) 
1  1.04  0.03  104.49  2.42 
5  4.82  0.16  96.46  3.29 
10  9.89  0.26  98.89  2.64 
20  20.19  0.33  100.96  1.62 
30  30.39  0.09  101.31  0.29 
0.1 N HCl 
solution 
pH 1.2 
40  39.66  0.36  99.15  0.92 
1  0.98  0.07  98.42  6.67 
5  4.77  0.17  95.40  3.58 
10  10.00  0.53  99.95  5.32 
20  20.42  0.31  102.10  1.53 
30  30.04  1.96  100.14  0.59 
Acetate 
buffer 
pH 4.5 
40  39.79  0.71  99.47  1.78 
1  1.04  0.05  103.91  5.02 
5  4.97  0.22  99.37  4.42 
10  10.08  0.14  100.85  1.39 
20  19.78  0.66  98.91  3.31 
30  30.14  0.59  100.46  1.95 
Phosphate 
buffer 
pH 6.8 
40  39.99  1.31  99.97  3.28 
 
 
              Table 3.  Optimal conditions for dissolution test of carvedilol tablets 
 
Condition  Data / Unit 
Apparatus  Apparatus II (Paddle) [26] 
Dissolution medium  Acetate buffer pH 4.5 
Volume of dissolution medium  900 ml 
Temperature of dissolution medium  370.5C 
Revolution of stirrer  50 rpm 
Number of tablet in vessel  1 tablet 
Sampling time  5, 10, 15, 20, 30 and 45 min 
Sampling volume  5.0 ml 
Medium replacement  Yes 
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Application to drug quality controls: comparison of dissolution profiles 
           Approval of multi-source formulations using comparative in vitro dissolution studies should be 
based on generation of comparative dissolution profiles rather than a single-point dissolution test [27]. 
When comparing the test and reference products, dissolution profile can be compared using f1 and f2. 
Two dissolution product profiles are declared similar if f1 is between 0-15 and f2 is between 50-100  
[28]. The results of dissolution efficiency in the three dissolution media, with Dilatrend
 and Brand A 
as reference and test products respectively, are presented in Table 4.     The dissolution profiles of 
6.25-mg and 12.5-mg formulations in all dissolution media show f1 and f2 within acceptable ranges. 
The results of the two formulations therefore reflect sameness of the two curves and thus equivalence 
of  the  in  vitro  performance  of  the  two  products.  On  the  contrary,  the  25-mg  formulation  shows 
disagreement with the above guideline. This difference might be due to the excipient in the formula 
and the size of tablet, both of which can vary among brands. It is then necessary to carry out an in vivo 
study to guarantee the bioequivalence between the products. 
 
 
Table 4.   The difference and similarity factors between Dilatrend
 (reference product) and Brand A 
(test product) in three different dissolution media 
 
6.25 mg  12.5 mg  25 mg  Dissolution medium 
f1  f2  f1  f2  f1  f2 
pH 1.2 
0.1 N HCl solution 
4.20  69.41  7.71  56.36  41.30  28.52 
pH 4.5 
acetate buffer 
5.75  61.59  0.89  88.24  10.36  38.46 
pH 6.8 
phosphate buffer 
6.15  68.96  7.56  68.02  17.59  55.74 
f1 = difference factor (0-15), f2 = similarity factor (50-100) 
 
 
Assay in tablet formulation 
The validated HPLC assay was applied to the quality control of two products. The % labelled 
amount and content uniformity are presented in Table 5. None of the formulation tested contains less 
than  95%  of  the  labelled  amount.  Results  of  content  uniformity  experiment  show  that  carvedilol 
content in each tablet from every product examined is in the range of 85.0-115.0 % and the RSD 
values are less than 6%. According to the acceptance limit of pharmacopoeia [24], this indicates a 
uniform distribution of drug in the tablets without any significant variation. 
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Figure 3.   Dissolution profiles of carvedilol tablets (Dilatrend
®) in: (A) 0.1 N HCl solution pH 1.2; 
(B) acetate buffer pH 4.5; (C) phosphate buffer pH 6.8  
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              Table 5.  Content of carvedilol in Dilatrend
 and Brand A tablets
 
 
  Dose  Dilatrend
  Brand A 
6.25 mg  95.820.45  97.741.27 
12.5 mg  98.070.93  95.710.38 
% Labelled 
amount 
(Mean  SD)  25 mg  97.780.80  96.760.90 
6.25 mg  95.76-99.18 (1.38)  96.02-102.73 (1.89) 
12.5 mg  94.44-97.51 (1.02)  93.55-97.60 (1.67) 
Content 
uniformity 
(Range in %)  25 mg  95.01-99.30 (1.36)  97.01-100.65 (1.45) 
Note:  Numbers in parentheses represent % RSD. 
 
 
Conclusions 
    A method of quantitative determination of carvedilol using HPLC with fluorescence detector has 
been developed for the dissolution test and the quality control of the tablet formulation. The validation 
results have demonstrated that this method is accurate, precise, linear and specific. The dissolution test 
developed for carvedilol tablets is considered satisfactory. The optimal conditions for the dissolution 
profile determination are: 900 ml of acetate buffer (pH 4.5) medium at 370.5C and paddle apparatus 
with 50-rpm stirring speed. The drug delivery requirement should be at least 80% dissolved in 30 min. 
The method can also be applied for quality control of drug content in pharmaceutical preparations. 
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